Giant Biogene Moves to Replace EY With KPMG as Auditor

Giant Biogene Holding Co. Ltd. ( (HK:2367) ) just unveiled an update.

Giant Biogene Holding Co. Ltd. has launched a planned change of auditors as part of its corporate governance review, deciding not to reappoint Ernst & Young after seven consecutive years of auditing its consolidated financial statements. EY will complete the audit for the year ended 31 December 2025 and retire at the conclusion of the upcoming annual general meeting, with the company stressing that the move will not affect the 2025 audit.

The board, following the audit committee’s recommendation, will seek shareholder approval at the AGM to appoint KPMG as the new auditor from the end of that meeting until the next annual general meeting. The audit committee cited KPMG’s scale, technical competence, independence, resources, and alignment with regulatory guidance as key reasons for its selection, and both EY and the board confirmed there are no disagreements or issues requiring shareholder attention, indicating a smooth transition with no expected disruption to the 2026 audit timetable.

The most recent analyst rating on (HK:2367) stock is a Hold with a HK$35.00 price target. To see the full list of analyst forecasts on Giant Biogene Holding Co. Ltd. stock, see the HK:2367 Stock Forecast page.

More about Giant Biogene Holding Co. Ltd.

Giant Biogene Holding Co. Ltd. is a Hong Kong-listed company engaged in the biopharmaceutical sector, operating through a group structure with various subsidiaries. The group focuses on producing and developing specialized biological products, positioning itself within regulated capital markets that emphasize strong corporate governance standards.

Average Trading Volume: 5,421,433

Technical Sentiment Signal: Sell

Current Market Cap: HK$31.22B

For detailed information about 2367 stock, go to TipRanks’ Stock Analysis page.